Rachel Hodge

14.6k citations

40 papers · 2.1k indexed · 2 hit papers · h-index 20

Pulmonary and Respiratory Medicine top 1%
Oncology top 2%
Molecular Biology
Cancer Research top 5%
Genetics top 10%

Co-authors: Suresh S. Ramalingam Andy Brown Isamu Okamoto Myung‐Ju Ahn Mireille Cantarini Naoyuki Nogami Nobuyuki Katakami James Chih‐Hsin Yang
Topics: Lung Cancer Treatments and Mutations (22 papers)Colorectal Cancer Treatments and Studies (11 papers)Lung Cancer Research Studies (9 papers)
Cited by: Pulmonary and Respiratory Medicine Oncology Cancer Research
Journals: Journal of Clinical Oncology Cancer The Plant Journal
Partner nations: United Kingdom United States Japan

In The Last Decade

Rachel Hodge

40 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

2018 511 citations Thanyanan Reungwetwattana, Kazuhiko Nakagawa et al. Journal of Clinical Oncology profile →
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

2018 349 citations Yi‐Long Wu, Myung‐Ju Ahn et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Rachel Hodge

Since Specialization

Citations

This map shows the geographic impact of Rachel Hodge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel Hodge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel Hodge more than expected).

Fields of papers citing papers by Rachel Hodge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel Hodge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel Hodge. The network helps show where Rachel Hodge may publish in the future.

Co-authorship network of co-authors of Rachel Hodge

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel Hodge. A scholar is included among the top collaborators of Rachel Hodge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel Hodge. Rachel Hodge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Conceptual framework of women’s food environments and determinants of food acquisition and dietary intake in low- and middle-income countries: a scoping review 2025 ·The Lancet Planetary Health ·(unknown),Julia de Bruyn,(unknown),Marta Fajó‐Pascual,Rachel Hodge,Christopher Turner,(unknown),Kate Wellard,Elaine Ferguson,Paula Domínguez-Salas	1
2	Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non–Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic 2023 ·Journal of Molecular Diagnostics ·Jhanelle E. Gray,Ji‐Youn Han,(unknown),Xiangning Huang,Alexander Kohlmann,Rachel Hodge,Yuri Rukazenkov,Juliann Chmielecki,Carin R. Espenschied,Martina I. Lefterova,Yi‐Long Wu,Suresh S. Ramalingam,J. Carl Barrett,Justin I. Odegaard	4
3	Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non–small-cell Lung Cancer: LAURA Trial in Progress 2021 ·Clinical Lung Cancer ·Shun Lü,Ignacio Casarini,Terufumi Kato,Manuel Cobo,Mustafa Özgüroğlu,Rachel Hodge,Toon van der Gronde,Matilde Saggese,Suresh S. Ramalingam	43
4	Estimating long-term survival of previously untreated patients with EGFR mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC) who received osimertinib in the FLAURA study. 2019 ·Journal of Clinical Oncology ·Matthew Dyer,Matthew Green,Simon W. Jones,Rachel Hodge	1
5	CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)breakdown → 2018 ·Journal of Clinical Oncology ·Yi‐Long Wu,Myung‐Ju Ahn,Marina Chiara Garassino,Ji‐Youn Han,Nobuyuki Katakami,Hye Ryun Kim,Rachel Hodge,Paramjit Kaur,Andy Brown,Dana Ghiorghiu,Vassiliki A. Papadimitrakopoulou,Tony Mok	349
6	Osimertinib in patients with epidermal growth factor receptor T790M advanced non‐small cell lung cancer selected using cytology samples 2018 ·Cancer Science ·Katsuyuki Kiura,Kiyotaka Yoh,Nobuyuki Katakami,Naoyuki Nogami,Kazuo Kasahara,Toshiaki Takahashi,Isamu Okamoto,Mireille Cantarini,Rachel Hodge,(unknown)	11
7	Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer 2017 ·Journal of Thoracic Oncology ·Suzanne Jenkins,James Chih‐Hsin Yang,Suresh S. Ramalingam,Karen Yu,S. Patel,Susie Weston,Rachel Hodge,Mireille Cantarini,Pasi A. Jänne,Tetsuya Mitsudomi,Glenwood Goss	221
8	EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib 2017 ·Journal of Thoracic Oncology ·Suzanne Jenkins,James Chih‐Hsin Yang,Pasi A. Jänne,Kenneth S. Thress,Karen Yu,Rachel Hodge,Susie Weston,Simon Dearden,S. Patel,Mireille Cantarini,Frances A. Shepherd	46
9	Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA 2017 ·Annals of Oncology ·Sundar Ramalingam,Thanyanan Reungwetwattana,(unknown),Arunee Dechaphunkul,K.H. Lee,Fumio Imamura,Naoyuki Nogami,Yuichiro Ohe,Ying Cheng,Byoung Chul Cho,(unknown),Johan Vansteenkiste,(unknown),Chao Zhou,Jhanelle E. Gray,Rachel Hodge,Yuri Rukazenkov,J.C. Soria	20
10	Osimertinib vs standard of care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA 2017 ·Annals of Oncology ·Yuichiro Ohe,Suresh S. Ramalingam,Thanyanan Reungwetwattana,(unknown),Arunee Dechaphunkul,K.H. Lee,Fumio Imamura,Naoyuki Nogami,Ying Cheng,Byoung Chul Cho,(unknown),Johan Vansteenkiste,(unknown),C. Zhou,Jhanelle E. Gray,Rachel Hodge,Yuri Rukazenkov,Jean‐Charles Soria	1
11	MA16.11 CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC: Pooled Data from Two Phase II Trials 2017 ·Journal of Thoracic Oncology ·Glenwood Goss,Chun‐Ming Tsai,Frances A. Shepherd,Myung‐Ju Ahn,Lyudmila Bazhenova,Lucio Crinò,Filippo de Marinis,Enriqueta Felip,Alessandro Morabito,Rachel Hodge,Mireille Cantarini,Tetsuya Mitsudomi,Pasi A. Jänne,James Chih‐Hsin Yang	23
12	MA08.03 Osimertinib vs Platinum-Pemetrexed for T790M-Mutation Positive Advanced NSCLC (AURA3): Plasma ctDNA Analysis 2017 ·Journal of Thoracic Oncology ·Yi‐Long Wu,Suzanne Jenkins,Suresh S. Ramalingam,Ji‐Youn Han,Angelo Delmonte,Te‐Chun Hsia,Janessa Laskin,Sang‐We Kim,Yong He,S. Patel,Rachel Hodge,Marcelo Marotti,Vassiliki A. Papadimitrakopoulou,Tony Mok	22
13	CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study 2017 ·Annals of Oncology ·Johan Vansteenkiste,Thanyanan Reungwetwattana,Kazuhiko Nakagawa,(unknown),(unknown),(unknown),A. Bertolini,Sabine Bohnet,C. Zhou,(unknown),Naoyuki Nogami,Isamu Okamoto,Natasha B. Leighl,Rachel Hodge,Astrid McKeown,Andy Brown,Yuri Rukazenkov,S. Ramalingam	27
14	CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study 2017 ·Annals of Oncology ·Johan Vansteenkiste,Thanyanan Reungwetwattana,Ken Nakagawa,Byoung Chul Cho,(unknown),(unknown),A. Bertolini,Sabine Bohnet,(unknown),(unknown),Naoyuki Nogami,Isamu Okamoto,Natasha B. Leighl,Rachel Hodge,Astrid McKeown,Aaron Brown,Yuri Rukazenkov,Sundar Ramalingam	11
15	Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy 2015 ·Fernando J. Martínez,Peter M.A. Calverley,Udo-Michael Goehring,Rachel Hodge,Leonardo M. Fabbri,Klaus F. Rabe	3
16	Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072 2014 ·Annals of Oncology ·Bernd Kasper,Stefan Sleijfer,Saskia Litière,Sandrine Marréaud,Jaap Verweij,Rachel Hodge,Sebastian Bauer,J. Martijn Kerst,Winette T.A. van der Graaf	89
17	Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial 2011 ·European Journal of Cancer ·David Cella,A. Simon Pickard,Mei Sheng Duh,A. Guérin,(unknown),(unknown),Maureen P. Neary,Lauren McCann,Rachel Hodge,Cora N. Sternberg	35
18	A Randomized, Double-Blind, Placebo-Controlled Trial of a Selective COX-2 Inhibitor, GW406381, in Patients With Postherpetic Neuralgia 2009 ·Journal of Pain ·(unknown),Richard Rauck,Steve Quessy,David Blum,Rachel Hodge,Richard Philipson	16
19	Characterization of a new class of oleosins suggests a male gametophyte-specific lipid storage pathway 1993 ·The Plant Journal ·Michael Roberts,Rachel Hodge,(unknown),(unknown),Denis J. Murphy,John Draper,Rod C. Scott	2
20	Radial forearm flap for floor of mouth reconstruction 1985 ·British journal of surgery ·R.N. Matthews,Rachel Hodge,(unknown),D M Davies,(unknown)	7

About Rachel Hodge

Rachel Hodge is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research, having authored 40 papers that have together received 2.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (22 papers), Colorectal Cancer Treatments and Studies (11 papers) and Lung Cancer Research Studies (9 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.9k citations), Oncology (1.5k citations) and Cancer Research (394 citations). Rachel Hodge has collaborated with scholars based in United Kingdom, United States and Japan. Frequent co-authors include Suresh S. Ramalingam, Andy Brown, Isamu Okamoto, Myung‐Ju Ahn, Mireille Cantarini, Naoyuki Nogami, Nobuyuki Katakami, James Chih‐Hsin Yang, Pasi A. Jänne and Kazuhiko Nakagawa. Their work appears in journals such as Journal of Clinical Oncology, Cancer and The Plant Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact